Inhibition of the prolyl isomerase Pin1 improves endothelial function and attenuates vascular remodelling in pulmonary hypertension by inhibiting TGF-β signalling.

"Declarations Conflicts of interestAll the authors declared that they have no conflict of interest. Ethical approvalThe institutional review board (IRB) for human studies of the VU University Medical Center (Amsterdam, the Netherlands) approved the study protocols (non-WMO, 2012/306). Human and animal rightsAll animal experiments were approved by the Dutch Central Ethical Committee for Animal Experiments and the Animal Care Committee of the University Medical Center Groningen and were carried out in compliance with guidelines issued by the Dutch government. Informed consentWritten informed consent for the collection of material and publication of results was obtained from the subjects or their surrogates, if required. Conflicts of interest All the authors declared that they have no conflict of interest."

"Funding We acknowledge support from the Netherlands CardioVascular Research Initiative: the Dutch Heart Foundation, Dutch Federation of University Medical Centers, the Netherlands Organization for Health Research and Development, and the Royal Netherlands Academy of Sciences Grant 2012–2008 and 2018–2023 awarded to the Phaedra consortium (http://www.phaedraresearch.nl). We also acknowledge support from the Stichting Hartekind and the Sebald fund and support for KK by the Dutch lung foundation grant number-5.2.17.198J0, and Leiden University Foundation grant- W18378-2-32."